KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Gains from Investment Securities: 2019-2025

Historic Gains from Investment Securities for Royalty Pharma (RPRX) over the last 4 years, with Mar 2025 value amounting to $13.4 million.

  • Royalty Pharma's Gains from Investment Securities changed negligibly% to $13.4 million in Q1 2025 from the same period last year, while for Mar 2025 it was $31.7 million, marking a year-over-year decrease of 1.58%. This contributed to the annual value of $18.0 million for FY2024, which is 4.37% down from last year.
  • As of Q1 2025, Royalty Pharma's Gains from Investment Securities stood at $13.4 million, which was up 190.96% from $4.6 million recorded in Q2 2024.
  • Over the past 5 years, Royalty Pharma's Gains from Investment Securities peaked at $20.7 million during Q1 2022, and registered a low of $313,000 during Q3 2023.
  • In the last 3 years, Royalty Pharma's Gains from Investment Securities had a median value of $9.0 million in 2024 and averaged $8.4 million.
  • In the last 5 years, Royalty Pharma's Gains from Investment Securities crashed by 94.62% in 2023 and then surged by 105.26% in 2024.
  • Quarterly analysis of 5 years shows Royalty Pharma's Gains from Investment Securities stood at $6.5 million in 2021, then fell by 10.85% to $5.8 million in 2022, then slumped by 94.62% to $313,000 in 2023, then skyrocketed by 105.26% to $4.6 million in 2024, then remained steady at $13.4 million in 2025.
  • Its Gains from Investment Securities stands at $13.4 million for Q1 2025, versus $4.6 million for Q2 2024 and $13.4 million for Q1 2024.